ReviewAbdominal radiology (New York)2021
CT appearance of gastrointestinal tract mucormycosis.
Review in Abdominal radiology (New York), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- A retrospective analysis for the management of oromaxillofacial invasive mucormycosis and systematic literature review.BMC oral health · 2023Pooled it
- Review
- Invasive Gastrointestinal Mucormycosis Presenting as Neutropenic Enterocolitis: A Case Report.The American journal of case reports · 2025Article
- Esophageal mucormycosis following bone marrow transplantation: An uncommon entity.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2025Article
- Gastrointestinal and Intra-Abdominal Mucormycosis in Non-Haematological Patients-A Comprehensive Review.Journal of fungi (Basel, Switzerland) · 2025Review
- Article
- Diverse Clinical Manifestations and Challenges of Mucormycosis: Insights From Serial Cases.Open forum infectious diseases · 2023Article
- Invasive Gastrointestinal Mucormycosis.ACG case reports journal · 2023Article
- Rise of mucormycosis during the COVID-19 pandemic and the challenges faced.Current medical mycology · 2023Review
- Adoption value of support vector machine algorithm-based computed tomography imaging in the diagnosis of secondary pulmonary fungal infections in patients with malignant hematological disorders.Open life sciences · 2023Article
- Mucor and Malignancy: A Double-Hit Case of Intestinal Ischemia.ACG case reports journal · 2022Article
- An old confusion: Entomophthoromycosis versus mucormycosis and their main differences.Frontiers in microbiology · 2022Review
- Machine learning based predictive model and systems-level network of host-microbe interactions in post-COVID-19 mucormycosis.Microbial pathogenesis · 2022Article
- COVID-19 Associated Mucormycosis: A Systematic Review from Diagnostic Challenges to Management.Diseases (Basel, Switzerland) · 2021Review
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucormycosis is a fungal infection caused by fungi of order mucorales. It is most commonly seen in patients with an impaired immune system due to any cause. Gastrointestinal mucormycosis is the least frequent type and may be a primary disease or a feature of generalized mucormycosis. Angioinvasion is the hallmark feature of mucormycosis, leading to bowel infarction which is the responsible for the most common clinical complaint of pain, and is also responsible for most of the imaging findings in this disease. The stomach is most commonly involved organ in the gastrointestinal tract and pneumatosis and lack of gastric wall enhancement are the most common imaging findings. Areas of bowel wall thickening and/ or lack of enhancement are seen in small bowel mucor and perforation can occur due to ischemia. Colonic mucor can present with mural thickening, or complete lack of definition or 'disappearance' of bowel wall with associated air containing collections. Mucormycosis affecting the bowel has a high mortality rate and early recognition and intervention may improve patient outcomes significantly. It should be suspected in immunosuppressed patients with imaging findings of unexplained bowel ischemia, infarction and/or pneumatosis without any obvious visible vascular thrombus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.